Compare Quest Diagnostics Inc (DGX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Weibo Corp — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Weibo Corp trades at $7.77 (market cap $1.88B). The key difference: Quest Diagnostics Inc is far larger — about 12.1× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.96%). Which is the better fit depends on your goals.
| DGX | WB | |
|---|---|---|
Market Cap | $22.80B | $1.88B |
Sector | Health | Media |
52-Week High | $216.02 | $12.83 |
52-Week Low | $166.42 | $7.20 |
Enterprise Value | $28.82B | $1.16B |
Dividend Yield | 1.67% | 7.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Weibo (WB) trades at $7.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong valuation metrics including a P/E of 5.37 and P/B of 0.49. The company reported $449.02M net income for 2025 with a 25.55% margin, though recent quarters saw EPS misses. A $0.61 dividend for H1-26 is scheduled, and cash flow trends show improvement in 2025. Analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. Upside is supported by low multiples and robust cash flow, but risks include user engagement challenges from rivals like Douyin and inconsistent earnings performance. The stock presents a value opportunity with income, yet requires monitoring of competitive and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
